TERABIT study

TERABIT Study

randomized controlled trial of daily TEriparatide, weekly teripaRAtide, or BIsphosphonaTe in patients with osteoporosis.

Patients

     women with primary osteoporosis and history of fragility fracture 131

     A) daily Teriparatide             46

     B) weekly Teriparatide          45

     C) oral Bisphosphonate        40

 Endpoints 

                                              0   6  18 months

DXA                                       ○   ○   ○

 (L-spine, femur)

X-ray                                      ○   ○   ○

 (spine, pelvis)

Blood test                               ○   ○   ○

 (bone turnover marker)

QCT                                        ○         ○

 (spine, femur)

HR-pQCT                                ○   ○    ○

 (radius, tibia)

Study framework

1) TERABIT study : focusing on DXA and Bone metabolic marker

2) TERABIT QCT study : focusing on QCT

3) TERABIT HR-pQCT study : focusing on HR-pQCT

Update

     2016.01.05 started

     2016.02.23 FPI

     2017.08.04 LPI

     2019.08.26 LPO